Doptelet Approval History
Reviewed by J.Stewart B.Pharm. Last updated on May 23, 2018.
FDA Approved: Yes (First approved May 21, 2018)
Brand name: Doptelet
Generic name: avatrombopag
Dosage form: Tablets
Company: Dova Pharmaceuticals, Inc.
Treatment for: Thrombocytopenia
Doptelet (avatrombopag) is a second generation, orally administered thrombopoietin receptor agonist (TPO-RA) indicated for the treatment of thrombocytopenia in patients with chronic liver disease who are scheduled to undergo a medical procedure.
Dosage and Administration
- Doptelet tablets should be taken orally with food once daily for five consecutive days.
- Dosing should begin 10 to 13 days prior to the scheduled medical or dental procedure, and the procedure should take place within 5 to 8 days after the last dose.
- The recommended dose is based on a patient’s platelet count prior to the scheduled procedure.
Warnings and Precautions
Thrombotic/Thromboembolic Complications: Doptelet is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease. Patients should be monitored carefully.
Most common adverse reactions (≥ 3%) include: pyrexia, abdominal pain, nausea, headache, fatigue, and peripheral edema.
Use In Specific Populations
- Pregnancy: Pregnant women should be advised of the potential risk to a fetus.
- Breastfeeding: Patients should not breastfeed during treatment with Doptelet, and for at least two weeks after taking the final dose.
Development History and FDA Approval Process for Doptelet
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.